Last updated: August 1, 2026
Iodixanol is an FDA-approved, nonionic, iso-osmolar iodinated contrast medium marketed primarily as Visipaque. Its clinical value is concentrated in angiography, computed tomography, digital subtraction angiography and urography for patients in whom lower-osmolar or iso-osmolar contrast selection is clinically relevant. The product has mature regulatory status, limited remaining patent protection and intense competition from iohexol, iopamidol, iopromide and ioversol.
Iodixanol demand should grow with imaging volumes, cardiovascular procedures and CT utilization, but price pressure, generic competition, hospital purchasing controls and supply-chain normalization will limit revenue growth. A reasonable base-case outlook is low- to mid-single-digit annual volume growth through 2030, with commercial growth below the broader contrast-media market unless the product retains a premium based on renal-risk positioning.
What is iodixanol and how is it used?
Iodixanol is a water-soluble, dimeric, nonionic contrast agent with an osmolality close to that of plasma at clinically used concentrations. Visipaque is supplied in multiple concentrations, including 270 and 320 mg iodine/mL formulations in the United States.
The FDA-approved label covers use in adults for:
- Intra-arterial digital subtraction angiography
- Intra-arterial conventional angiography
- Cerebral angiography
- Coronary angiography and left ventriculography
- Visceral and renal angiography
- Peripheral angiography
- Intravenous contrast-enhanced CT
- Intravenous digital subtraction angiography
- Excretory urography
Pediatric indications include intra-arterial angiography, intravenous contrast-enhanced CT and excretory urography, subject to age and procedure-specific labeling requirements. The product is administered intravenously or intra-arterially, depending on the diagnostic procedure. The FDA label warns about hypersensitivity reactions, acute kidney injury, thyroid dysfunction, extravasation and cardiovascular complications.[1]
Which companies manufacture or market iodixanol?
The principal branded product is Visipaque, historically associated with GE Healthcare and now within the GE HealthCare pharmaceutical diagnostics portfolio. Regional suppliers and generic manufacturers may market iodixanol injection under alternative names, depending on local approvals.
The competitive supplier group includes:
| Company |
Relevant contrast-media position |
| GE HealthCare |
Visipaque and Omnipaque |
| Bracco |
Iomeron and other iodinated agents |
| Bayer |
Ultravist |
| Guerbet |
Xenetix and related imaging agents |
| Hengrui Medicine |
Generic and branded contrast products in selected markets |
| Regional generic manufacturers |
Iodixanol and other iodinated contrast injections |
Product availability varies substantially by jurisdiction. A company may hold approval in one country without having a commercial presence in the United States or European Union.
What clinical trials have evaluated iodixanol?
Iodixanol has been studied extensively in comparative trials rather than as a new investigational drug. Most modern studies examine renal safety, cardiovascular procedures, contrast-associated acute kidney injury, image quality, hypersensitivity, thyroid effects and use in patients with chronic kidney disease.
What did clinical trials show about renal safety?
The central clinical rationale for iodixanol is its iso-osmolar profile. Early studies compared iodixanol with low-osmolar agents in patients at elevated risk of renal complications. Results generally showed lower or comparable rates of contrast-associated kidney injury in selected high-risk groups, particularly patients with diabetes, chronic kidney disease or intra-arterial exposure. Results were not uniform across all trials and depended on hydration, contrast dose, baseline kidney function and the comparator.
Large later trials questioned whether routine selection of iodixanol produces a major renal benefit over modern low-osmolar contrast media when contemporary preventive care is used. The PRESERVE trial evaluated strategies for preventing contrast-associated kidney injury in high-risk patients undergoing angiography. It found no significant benefit from sodium bicarbonate over sodium chloride or from oral acetylcysteine over placebo in the primary outcome.[2] The study evaluated prevention strategies rather than establishing iodixanol superiority.
Current clinical interpretation is narrower:
- Iodixanol remains a reasonable option for patients at increased renal risk.
- Iso-osmolar status does not eliminate the risk of acute kidney injury.
- Hydration, avoidance of excessive contrast volume and management of nephrotoxic exposures remain central.
- Evidence does not support universal use of iodixanol over all low-osmolar alternatives.
What other clinical uses are under study?
Clinical research involving iodixanol generally falls into four categories:
- Contrast-associated acute kidney injury prevention.
- Cardiovascular and peripheral angiographic imaging.
- CT imaging in patients with renal impairment.
- Contrast reaction, thyroid and post-procedure safety surveillance.
Iodixanol is also used as the procedural contrast agent in investigator-initiated trials where the research question concerns angiography, intervention, imaging quality or renal outcomes. These studies do not necessarily indicate a new label expansion or a new commercial indication.
The drug has no significant modern clinical-development program comparable to an innovative pharmaceutical. Its trial activity is primarily post-approval, comparative or health-outcomes research.
What is the FDA regulatory status of iodixanol?
Iodixanol is an established FDA-approved contrast medium. Visipaque is regulated as a prescription drug under an approved new drug application rather than as a biologic.
| Regulatory element |
Status |
| Active ingredient |
Iodixanol |
| Brand |
Visipaque |
| FDA pathway |
New Drug Application |
| Primary sponsor |
GE HealthCare-affiliated entity |
| Dosage form |
Injectable solution |
| Administration |
Intravenous and intra-arterial |
| Main uses |
CT, angiography, urography and related imaging |
| Regulatory stage |
Mature, post-approval product |
| Exclusivity profile |
Expired |
| Biosimilar pathway |
Not applicable |
The primary regulatory risks are manufacturing quality, sterility, supply continuity, labeling compliance and post-marketing adverse-event monitoring. Iodixanol is not a biologic, so biosimilar substitution rules do not apply.
What is the Orange Book status of Visipaque and iodixanol?
Visipaque is an older small-molecule injectable product. Its original market exclusivity and any regulatory exclusivity associated with the original approval have expired. The product does not have the type of active exclusivity profile associated with a recently approved drug.
The commercial question is therefore not whether a competitor can enter after a future loss-of-exclusivity event. It is whether a competing manufacturer can obtain approval, demonstrate pharmaceutical equivalence and meet the manufacturing requirements for a sterile injectable contrast agent.
Relevant Orange Book considerations include:
- FDA-listed reference product status for the branded product.
- Any current patent listings associated with the specific NDA.
- Approved strengths and dosage forms.
- ANDA approvals for equivalent iodixanol injections.
- Paragraph IV certifications, if filed against a listed patent.
The practical patent position is weak compared with newer specialty pharmaceuticals. The active-ingredient and core product patents that historically supported iodixanol commercialization are generally expired or commercially ineffective in the United States. Current entry barriers are more likely to arise from facility qualification, sterile manufacturing, supply contracts and regulatory execution than from blocking patents.[3]
What patents protect iodixanol?
The historical intellectual-property estate around iodixanol covered the compound, iodinated contrast formulations, manufacturing processes and selected pharmaceutical compositions. The earliest product and compound patents are no longer expected to provide meaningful exclusivity in major markets.
Potentially relevant IP categories include:
| IP category |
Current commercial relevance |
| Iodixanol compound patents |
Generally expired |
| Composition and concentration patents |
Generally expired or limited |
| Manufacturing-process patents |
May remain relevant only for specific processes |
| Container and packaging patents |
Usually narrow and non-blocking |
| Method-of-use patents |
Limited importance because core imaging uses are established |
| Device or injector patents |
May protect equipment, not iodixanol itself |
| Trade secrets |
Potentially relevant to yield, impurity control and process economics |
A competitor does not need to reproduce a proprietary manufacturing process if it can make iodixanol through a non-infringing route and satisfy FDA chemistry, manufacturing and controls requirements.
When did iodixanol lose exclusivity?
Iodixanol lost meaningful market exclusivity years ago. Its regulatory position is mature, and generic or alternative-source competition is legally possible in jurisdictions where approved products are available.
The relevant timeline is:
| Period |
Event |
| 1990s |
Iodixanol developed and introduced as an iso-osmolar contrast agent |
| 1995-1996 |
U.S. regulatory approval and commercial launch period for Visipaque |
| 2000s |
Expansion of comparative renal-safety and angiography evidence |
| 2010s |
Mature post-approval use and growing generic contrast competition |
| 2022 |
Global iodinated contrast supply disruption, including the Shanghai production interruption |
| 2023-2024 |
Supply normalization and continued price competition |
| 2025-2030 |
Expected incremental generic and regional-source competition |
The exact expiration date for an individual patent depends on the patent family, terminal disclaimers, jurisdiction and any applicable patent-term adjustment. No single patent expiration date defines the current commercial position of iodixanol.
Are there Paragraph IV challenges to iodixanol?
Paragraph IV litigation is not the principal market issue for iodixanol. The product is old, and any remaining patent disputes would likely involve a specific listed patent, formulation, manufacturing process or ANDA rather than the basic active ingredient.
Potential generic entry typically proceeds through:
- Identification of the reference listed drug.
- ANDA submission.
- Paragraph IV certification against any listed patents.
- Patent-holder notice and possible district-court litigation.
- FDA approval, subject to patent and regulatory conditions.
- Commercial launch under a generic or authorized-generic model.
The absence of a major, current Paragraph IV dispute does not eliminate competition. It indicates that the principal barriers have moved from patent enforcement to injectable-drug development and manufacturing.
What formulations are protected by iodixanol patents?
Iodixanol formulations are typically differentiated by concentration, container size, excipient profile, packaging and administration requirements. Commercially important strengths include 270 and 320 mg iodine/mL.
Formulation competition focuses on:
- Iodixanol concentration
- pH and osmolality control
- Stability during storage
- Extractables and leachables
- Container-closure integrity
- Sterility assurance
- Compatibility with automated injectors
- Dose volume and iodine delivery
Formulation patents have limited value when the product is already mature unless they protect a clinically meaningful, hard-to-reproduce formulation or a specific delivery system. Regulatory approval of an equivalent injectable can create a more immediate competitive threat than a narrow formulation patent can prevent.
What patent litigation and settlement agreements affect iodixanol?
Iodixanol has not generated a major current patent-litigation profile comparable to high-value oncology, immunology or rare-disease drugs. The lack of prominent active litigation reflects the age of the product and the limited value of extending exclusivity through late-stage patent enforcement.
Settlement economics are also different from those of a blockbuster oral drug. Contrast agents are purchased through hospitals, group purchasing organizations, radiology departments and procedure contracts. A settlement that delays entry may have less value when multiple alternative contrast agents are already available.
How strong is the iodixanol patent estate?
The patent estate is weak as a current exclusivity instrument and moderate as a historical technology estate.
| Factor |
Assessment |
| Core compound protection |
Expired or commercially exhausted |
| Regulatory exclusivity |
Expired |
| Formulation protection |
Narrow and product-specific |
| Manufacturing know-how |
Potentially meaningful |
| Device integration |
Relevant to workflow, not active-ingredient exclusivity |
| Litigation leverage |
Low |
| Generic entry exposure |
Moderate to high |
| Supply-chain barrier |
Moderate |
| Brand and clinical familiarity |
Moderate |
The strongest remaining defenses are commercial. They include physician familiarity, formulary placement, global distribution, validated production capacity, quality history and contractual relationships with hospitals and imaging networks.
What is the iodixanol market size and growth outlook?
Iodixanol revenue is usually reported within broader iodinated contrast-media or diagnostic-imaging pharmaceutical markets rather than as a standalone public segment. Public company disclosures generally do not isolate Visipaque sales by product, geography or indication.
A practical market model uses the following variables:
- Global CT and angiography procedure growth
- Cardiovascular intervention volumes
- Renal-risk patient mix
- Average iodine dose per procedure
- Generic penetration
- Hospital tender pricing
- Supply-chain reliability
- Product substitution by iohexol, iopamidol, iopromide and ioversol
Base-case projection, 2025-2030
| Metric |
Base-case outlook |
| Procedure-driven volume growth |
3%-5% annually |
| Iodixanol unit growth |
2%-4% annually |
| Average selling price |
Flat to down 2% annually |
| Revenue growth |
0%-3% annually |
| Generic and regional-source pressure |
Increasing |
| Premium preservation |
Strongest in high-risk and interventional segments |
| Overall market profile |
Mature, defensive, low-growth |
The broader global contrast-media market may grow faster than iodixanol because of overall imaging expansion, new injector systems, procedure recovery and emerging-market demand. Iodixanol is unlikely to capture all of that growth because its premium positioning is contested by modern low-osmolar agents.
Bull case
A higher-growth scenario would require sustained growth in CT and angiography, continued clinician preference for iso-osmolar contrast in chronic kidney disease and limited generic supply. Under that scenario, iodixanol revenue could grow at approximately 3%-5% annually through 2030.
Bear case
A lower-growth scenario would involve hospital tender substitution, broader use of low-cost iohexol and iopamidol, generic iodixanol approval, and price reductions following supply normalization. Revenue could decline at approximately 2%-5% annually even if procedure volumes rise.
How does iodixanol compare with competing contrast agents?
| Product |
Active ingredient |
Osmolality profile |
Main competitive position |
| Visipaque |
Iodixanol |
Iso-osmolar |
Renal-risk positioning and angiography |
| Omnipaque |
Iohexol |
Low-osmolar |
Broad use, strong availability and cost competition |
| Isovue |
Iopamidol |
Low-osmolar |
Broad CT and angiography use |
| Ultravist |
Iopromide |
Low-osmolar |
CT and angiography |
| Optiray |
Ioversol |
Low-osmolar |
Imaging and interventional use |
| Iomeron |
Iomeprol |
Low-osmolar |
International market presence |
Iodixanol’s main differentiator is its iso-osmolar profile, not a unique diagnostic indication. In routine CT, purchasing departments may favor lower-cost products when clinical outcomes and image quality are considered equivalent. In high-risk angiography, clinicians may continue to select iodixanol based on patient factors and local protocols.
What generic entry risks exist for iodixanol?
Generic entry risk is moderate to high over the long term. The risk is greater in price-sensitive hospital systems and lower where the branded product has established supply contracts or strong quality differentiation.
Key entry barriers include:
- Complex sterile injectable manufacturing
- High cost of validated production lines
- Need for reliable iodine and precursor supply
- Batch sterility and particulate-control requirements
- Stability and container-closure testing
- FDA inspection readiness
- Hospital formulary conversion
- Need for uninterrupted supply during tenders
A successful generic entrant could pressure price through hospital tenders without displacing the branded product in every account. Authorized-generic or regional partnerships could accelerate penetration.
What is the regulatory and commercial outlook for iodixanol?
Iodixanol will remain a commercially relevant contrast agent because it is approved, clinically familiar and integrated into diagnostic workflows. The product does not have the growth profile of an innovative medicine. Its outlook depends on imaging volumes, procurement economics and the perceived value of iso-osmolar contrast in renal-risk populations.
The strongest commercial opportunities are:
- Interventional cardiology
- High-risk angiography
- Hospitals with established Visipaque protocols
- Markets with rising CT and cardiovascular procedure volumes
- Supply-constrained regions where product reliability carries a premium
The main risks are:
- Generic price erosion
- Substitution by low-osmolar agents
- Hospital purchasing consolidation
- Reduced use of contrast in selected CT protocols
- Supply interruptions
- Lack of new proprietary indications
- Limited patent leverage
Key Takeaways
- Iodixanol, marketed as Visipaque, is a mature FDA-approved iso-osmolar iodinated contrast agent.
- Its primary uses are CT, angiography, digital subtraction angiography and urography.
- Clinical research is concentrated on renal safety, cardiovascular imaging and post-approval outcomes.
- Modern evidence does not establish universal superiority over low-osmolar contrast agents.
- Regulatory exclusivity and meaningful core patent protection have expired.
- Biosimilar risk is irrelevant because iodixanol is a small-molecule injectable, not a biologic.
- Generic entry risk is moderate to high, with sterile manufacturing and supply reliability as the main barriers.
- Revenue growth through 2030 is likely to remain low, with a base-case range of 0%-3% annually.
- Iodixanol’s strongest commercial position is in high-risk angiography and established hospital protocols.
- The principal competitive threats are iohexol, iopamidol, iopromide, ioversol and lower-priced generic suppliers.
FAQs
Is iodixanol still under patent protection?
The original compound and core product protections are generally expired or commercially exhausted. Narrow process, packaging or formulation rights may exist in particular jurisdictions, but they are unlikely to create broad market exclusivity.
Is iodixanol safer for kidneys than iohexol?
Iodixanol has an iso-osmolar profile and may be selected for patients at elevated renal risk. Comparative evidence does not support assuming a major renal-safety advantage in every patient or procedure.
Does iodixanol have biosimilars?
No. Biosimilars apply to biological products. Iodixanol is a chemically synthesized small-molecule contrast agent, so competitors enter through generic-drug and injectable-equivalence pathways.
Which drug competes most directly with Visipaque?
Iohexol, marketed as Omnipaque, is the closest broad commercial competitor. Iopamidol, iopromide and ioversol also compete across CT, angiography and interventional imaging.
Could iodixanol sales decline even if imaging volumes increase?
Yes. Higher procedure volumes can be offset by hospital tender discounts, substitution with lower-cost low-osmolar agents, generic entry and lower average selling prices.
References
-
U.S. Food and Drug Administration. (2023). Visipaque-270 and Visipaque-320 iodixanol injection prescribing information. FDA.
-
Weisbord, S. D., Gallagher, M., Jneid, H., Garcia, S., Cass, A., Parfrey, P., et al. (2018). Outcomes after angiography with sodium bicarbonate and acetylcysteine. New England Journal of Medicine, 378(7), 603-614. https://doi.org/10.1056/NEJMoa1710933
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
GE HealthCare. (2024). Annual report 2023. GE HealthCare Technologies Inc.
-
U.S. National Library of Medicine. (2024). ClinicalTrials.gov database. National Institutes of Health.
